Jared Kelly
Vermogen: 118 612 $ op 31-05-2026
Vermogen: 118 612 $ op 31-05-2026
Jared Kelly is currently Chief Executive Officer & Director at Oncolytics Biotech, Inc. since 2025.
Mr. Kelly is also Secretary, Senior Vice President & General Counsel at Ambrx Biopharma Cayman, Inc. since 2023.
Formerly, Mr. Kelly was a Partner at Lowenstein Sandler LLP.
Mr. Kelly completed graduate studies at Georgetown University Law Center.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-06-2026 | 114.050 ( 0,1% ) | 118 612 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Algemeen Directeur | 11-06-2025 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Algemeen Adviseur | 13-09-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Georgetown University Law Center
Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau